Form 4: Akero Therapeutics CDO Sells Shares Post-Novo Merger

Akero Therapeutics' Chief Development Officer, Catriona Yale, disposed of common stock, RSUs, and stock options following the company's merger with Novo Nordisk, receiving cash and contingent value rights.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, Inc. (AKRO), reported the disposition of her beneficial ownership in the company.
• The disposition occurred on December 9, 2025, which was the effective date of the merger between Akero Therapeutics and NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• Under the merger agreement, Akero Therapeutics became a wholly-owned subsidiary of Novo Nordisk.
• Ms. Yale disposed of 27,227 shares of common stock, which were converted into the right to receive $54.00 in cash per share and one contractual contingent value right (CVR) for an additional $6.00 in cash if a specified milestone is achieved.
• She also disposed of 47,573 restricted stock units (RSUs), which were deemed fully vested and converted into the same merger consideration per unit.
• Additionally, Ms. Yale disposed of stock options representing the right to buy a total of 456,575 shares of common stock, which were deemed fully vested and converted into a cash payment equal to the excess of the $54.00 Closing Consideration over the option's exercise price, plus one CVR per underlying share.
• The exercise prices for the disposed stock options ranged from $19.87 to $42.95.

Sentiment

Score: 7

Explanation: The sentiment is positive as the filing reports the successful completion of a merger, providing a clear exit and value for shareholders, including the reporting insider. The CVR adds potential upside, though with inherent contingency.

Positives

• The merger provided a clear liquidity event for shareholders, including the reporting person, converting equity holdings into cash and CVRs.
• The reporting person received a fixed cash payment of $54.00 per share/unit/option, providing certainty of value for a significant portion of her equity.
• The potential for an additional $6.00 per share/unit/option via the CVR offers upside if the specified milestone is achieved.

Negatives

• The contingent nature of the $6.00 CVR means that portion of the merger consideration is not guaranteed and depends on a future milestone.

Risks

• The achievement of the specified milestone for the $6.00 contingent value right (CVR) is uncertain, meaning the full potential merger consideration of $60.00 per share/unit/option may not be realized.

Future Outlook

Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk A/S. The future outlook for the former public entity is integrated into Novo Nordisk's operations. The primary forward-looking element for former Akero shareholders is the potential achievement of the CVR milestone for an additional $6.00 per share.

Industry Context

This transaction reflects the ongoing trend of consolidation within the biopharmaceutical industry, where larger companies acquire smaller, innovative firms to bolster their pipelines and expand their therapeutic areas. The acquisition of Akero Therapeutics by Novo Nordisk highlights the value placed on Akero's development programs, particularly in metabolic diseases, by a major global pharmaceutical player.

Stakeholder Impact

• Shareholders of Akero Therapeutics received cash and CVRs for their shares, providing a return on their investment.
• Employees, including the Chief Development Officer, had their equity compensation converted into merger consideration, aligning their interests with the acquisition's success.

Next Steps

• Monitoring the progress towards the specified milestone for the $6.00 contingent value right (CVR) payment.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, RSU, Contingent Value Right, CVR, Biopharma